High-dose ibuprofen is safe and effective in slowing down lung disease in children with cystic fibrosis (CF), if the drug is used as part of routine therapy, shows a clinical trial. A team of researchers led by Dr. Larry Lands, Director of Pediatric Respiratory Medicine at Montreal Children’s Hospital of the McGill University Health Centre, monitored 142 children in the six to 18 years age group. The children had mild lung disease for over two years.
The researchers found that the administration of high-dose ibuprofen twice a day significantly reduced the rate of decline in lung function in children, and cut short hospital stays.
“Slowing the rate of the decline of lung function will result in enhanced longevity and quality of life for patients with CF,” said Dr. Larry Lands.
The researchers have hailed the new findings by saying that ibuprofen can offer a relatively inexpensive treatment for cystic fibrosis as compared to other therapies.
“Many treatments for cystic fibrosis can be a financial hardship for families. News that ibuprofen – a relatively inexpensive treatment compared to other therapies for CF – is effective, is very exciting,” said Cathleen Morrison, Chief Executive Officer at the Canadian Cystic Fibrosis Foundation.
"We are delighted to share this great news. The findings of this study show that through research and innovation, a simple inexpensive treatment can have a profound impact on the lives of children affected by CF and their families," said Dr. Peter Liu, Scientific Director of CIHR's Institute of Circulatory and Respiratory Health.